{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:55:39Z","timestamp":1788357339529,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["218950"],"award-info":[{"award-number":["218950"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.anai.2026.03.024","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T23:56:53Z","timestamp":1775260613000},"page":"44-52.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mepolizumab exhibits quantifiable reduction in corticosteroid-related adverse effects in severe asthma"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0235-7105","authenticated-orcid":false,"given":"Njira L.","family":"Lugogo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijita","family":"Deb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2026.03.024_bib0001","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Accessed October 25, 2024. Available at: https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/05\/GINA-2024-Strategy-Report-24_05_22_WMS.pdf"},{"issue":"2","key":"10.1016\/j.anai.2026.03.024_bib0002","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.anai.2022.02.021","article-title":"Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions","volume":"129","author":"Oppenheimer","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2026.03.024_bib0003","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2147\/JAA.S327659","article-title":"Severe asthma in a general population study: prevalence and clinical characteristics","volume":"14","author":"R\u00f6nnebjerg","year":"2021","journal-title":"J Asthma Allergy"},{"issue":"2","key":"10.1016\/j.anai.2026.03.024_bib0004","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.anai.2026.03.024_bib0005","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s12325-023-02479-0","article-title":"A charter to fundamentally change the role of oral corticosteroids in the management of asthma","volume":"40","author":"Haughney","year":"2023","journal-title":"Adv Ther"},{"issue":"7","key":"10.1016\/j.anai.2026.03.024_bib0006","first-page":"833","article-title":"Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma","volume":"22","author":"Dalal","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"10.1016\/j.anai.2026.03.024_bib0007","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.anai.2026.03.024_bib0008","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.anai.2026.03.024_bib0009","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.anai.2026.03.024_bib0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"issue":"1","key":"10.1016\/j.anai.2026.03.024_bib0011","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12931-018-0742-y","article-title":"Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis","volume":"19","author":"Bloechliger","year":"2018","journal-title":"Respir Res"},{"issue":"8","key":"10.1016\/j.anai.2026.03.024_bib0012","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.jaip.2022.03.024","article-title":"Ten Brinke A. Overuse of oral corticosteroids in asthma is often underdiagnosed and inadequately addressed","volume":"10","author":"van der Meer","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.anai.2026.03.024_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-015905","article-title":"Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France","volume":"7","author":"B\u00e9nard-Laribi\u00e8re","year":"2017","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.anai.2026.03.024_bib0014","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02363-2019","article-title":"Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK","volume":"55","author":"Tran","year":"2020","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.anai.2026.03.024_bib0015","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaip.2018.10.016","article-title":"The severe asthma network in Italy: findings and perspectives","volume":"7","author":"Heffler","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2026.03.024_bib0016","first-page":"53","article-title":"Trends in systemic glucocorticoid utilization in the United Kingdom from 1990 to 2019: a population-based, serial cross-sectional analysis","volume":"15","author":"Menzies-Gow","year":"2024","journal-title":"Pragmat Obs Res"},{"issue":"4","key":"10.1016\/j.anai.2026.03.024_bib0017","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.anai.2025.07.026","article-title":"Corticosteroid stewardship: how much corticosteroid is too much?","volume":"135","author":"Szefler","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.anai.2026.03.024_bib0018","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jaip.2025.05.046","article-title":"Ushering in the era of corticosteroid stewardship: what is the impact of biologics on this asthma burden?","volume":"13","author":"Szefler","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.anai.2026.03.024_bib0019","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1164\/rccm.202501-0246OC","article-title":"Prevention of cardiovascular and other systemic adverse outcomes in patients with asthma treated with biologics","volume":"211","author":"Sadatsafavi","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2026.03.024_bib0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fmed.2018.00049","article-title":"Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma","volume":"5","author":"Roufosse","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.anai.2026.03.024_bib0021","unstructured":"Food and Drug Administration. Mepolizumab (Nucala) prescribing information. Accessed October 25, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125526Orig1s021,761122Orig1s011Corrected_lbl.pdf"},{"key":"10.1016\/j.anai.2026.03.024_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221107313","article-title":"Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies","volume":"16","author":"Casale","year":"2022","journal-title":"Ther Adv Respir Dis"},{"issue":"13","key":"10.1016\/j.anai.2026.03.024_bib0023","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.anai.2026.03.024_bib0024","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.anai.2026.03.024_bib0025","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A Study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2026.03.024_bib0026","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00151-2020","article-title":"Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis","volume":"56","author":"Harrison","year":"2020","journal-title":"Eur Respir J"},{"issue":"15","key":"10.1016\/j.anai.2026.03.024_bib0027","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"REal worlD Effectiveness and Safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES Study","volume":"81","author":"Domingo Ribas","year":"2021","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.anai.2026.03.024_bib0028","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2026.03.024_bib0029","series-title":"Corticosteroid adverse effects","author":"Yasir","year":"2023"},{"issue":"4","key":"10.1016\/j.anai.2026.03.024_bib0030","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clinthera.2013.03.001","article-title":"Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus","volume":"35","author":"Shah","year":"2013","journal-title":"Clin Ther"},{"issue":"12","key":"10.1016\/j.anai.2026.03.024_bib0031","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/pds.1673","article-title":"Goodness-of-fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score","volume":"17","author":"Austin","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.anai.2026.03.024_bib0032","unstructured":"U.S. Bureau of Labor Statistics. Consumer price index. Accessed July 7, 2024. Available at: https:\/\/data.bls.gov\/timeseries\/CUUR0000SAM?output_view=data"},{"issue":"1","key":"10.1016\/j.anai.2026.03.024_bib0033","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"3","key":"10.1016\/j.anai.2026.03.024_bib0034","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2026.03.024_bib0035","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1164\/rccm.202504-0927ED","article-title":"She loves me, she loves me not: do biologics decrease glucocorticoid morbidity in adults with severe T-helper cell Type 2 asthma?","volume":"211","author":"Gaston","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.anai.2026.03.024_bib0036","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.201207-1280OC","article-title":"Systemic steroid exposure is associated with differential methylation in chronic obstructive pulmonary disease","volume":"186","author":"Wan","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.anai.2026.03.024_bib0037","doi-asserted-by":"crossref","first-page":"316","DOI":"10.5694\/mja2.50758","article-title":"Cumulative dispensing of high oral corticosteroid doses for treating asthma in Australia","volume":"213","author":"Hew","year":"2020","journal-title":"Med J Aust"},{"issue":"11","key":"10.1016\/j.anai.2026.03.024_bib0038","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/all.13874","article-title":"Oral corticosteroid use, morbidity and mortality in asthma: a nationwide prospective cohort study in Sweden","volume":"74","author":"Ekstr\u00f6m","year":"2019","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2026.03.024_bib0039","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaip.2020.06.019","article-title":"Oral corticosteroid treatment patterns of patients in the United States with persistent asthma","volume":"9","author":"Tran","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2026.03.024_bib0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.chest.2022.01.071","article-title":"Dupilumab reduces oral corticosteroid use in patients with corticosteroid-dependent severe asthma: an analysis of the phase 3, open-label extension TRAVERSE trial","volume":"162","author":"Sher","year":"2022","journal-title":"Chest"},{"issue":"25","key":"10.1016\/j.anai.2026.03.024_bib0041","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid\u2013sparing effect of Benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.anai.2026.03.024_bib0042","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2026.03.024_bib0043","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/JAA.S236609","article-title":"Real-world effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs","volume":"13","author":"Llanos","year":"2020","journal-title":"J Asthma Allergy"},{"issue":"4","key":"10.1016\/j.anai.2026.03.024_bib0044","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jaci.2016.08.008","article-title":"Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma","volume":"139","author":"Yancey","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2026.03.024_bib0045","first-page":"1193","article-title":"A cost comparison of Benralizumab, mepolizumab, and dupilumab in patients with severe asthma: a US third-party payer perspective","volume":"29","author":"Xu","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.anai.2026.03.024_bib0046","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13223-024-00882-y","article-title":"Real-world association between systemic corticosteroid exposure and complications in US patients with severe asthma","volume":"20","author":"Casale","year":"2024","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.03.024_bib0047","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/02770903.2022.2102036","article-title":"Impact of mepolizumab in patients with high-burden severe asthma within a managed care population","volume":"60","author":"Lugogo","year":"2023","journal-title":"J Asthma"},{"issue":"5","key":"10.1016\/j.anai.2026.03.024_bib0048","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.adaj.2015.02.010","article-title":"The limitations of using insurance data for research","volume":"146","author":"Hyman","year":"2015","journal-title":"J Am Dent Assoc"},{"issue":"4","key":"10.1016\/j.anai.2026.03.024_bib0049","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4997\/jrcpe.2020.409","article-title":"Retrospective studies - utility and caveats","volume":"50","author":"Talari","year":"2020","journal-title":"J R Coll Physicians Edinb"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626001468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626001468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:17:18Z","timestamp":1782465438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626001468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1081120626001468"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.03.024","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mepolizumab exhibits quantifiable reduction in corticosteroid-related adverse effects in severe asthma","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}